ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy

Zhang, Yuxin; Zhang, Yujie; Tao, Haisu; Zhu, Jinghan; Lu, Yuanxiang; Cheng, Fangling; Xiong, Yixiao; Liu, Junjie; Cai, Guangzhen; Zhang, Zhanguo*; Liang, Huifang*; Chen, Yifa*; Zhang, Wanguang*华中科技大学; 南方医科大学
Cancer Letters2023-11-1DOI: 10.1016/j.canlet.2023.216405
1被引5阅读
引用收藏
分享

摘要

Lenvatinib is a standard therapy option for advanced hepatocellular carcinoma (HCC), but resistance limits clinical benefits. In this study, we identified inhibition of ROS levels and reduced redox status in Lenvatinibresistant HCC. Integrating RNA-seq with unbiased whole-genome CRISPR-Cas9 screen analysis indicated LINC01607 regulated the P62 to enhance drug resistance by affecting mitophagy and antioxidant pathways. Underlying mechanisms were investigated both in vitro and in vivo. We initially confirmed that LINC01607, as a competing endogenous RNA (ceRNA) competing with mirRNA-892b, triggered protective mitophagy by upregulating P62, which reduced ROS levels and promoted drug resistance. Furthermore, LINC01607 was proved to resist oxidative stress by regulating the P62-Nrf2 axis, which transcriptionally regulated the expression of LINC01607 to form a positive feedback loop. Finally, silencing LINC01607 combined with Lenvatinib reversed resistance in animal and patient-derived organoid models. In conclusion, we proposed a novel mechanism of Lenvatinib resistance involving ROS homeostasis. This work contributed to understanding redox homeostasisrelated drug resistance and provided new therapeutic targets and strategies for HCC patients.

学科与关键词

关键词
Hepatocellular carcinomaLenvatinib resistanceLINC01607P62Nrf2Mitophagy
相关
加载中…
  • MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met
    Xu, Xin; Jiang, Wenjing; Han, Peng; Zhang, Jingyan; Tong, Liquan*; Sun, Xueying*Journal of Hepatocellular Carcinoma, 2022, 9: 113-126.被引 13
  • Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
    Fu, Rongdang; Jiang, Shaotao; Li, Jieyuan; Chen, Huanwei*; Zhang, Xiaohong*MEDICAL ONCOLOGY, 2020, 37(4): 24.被引 62
  • Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma
    Huang, Shanzhou; Ma, Zuyi; Zhou, Qi; Wang, Aimei; Gong, Yuanfeng; Li, Zhenchong; Wang, Shujie; Yan, Qian; Wang, Dongping*; Hou, Baohua*; Zhang, Chuanzhao*International Journal of Biological Sciences, 2022, 18(11): 4357-4371.被引 15
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Letters
发表日期
2023-11-01
卷期
第 576 卷
页码
216405
DOI
10.1016/j.canlet.2023.216405
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82173319, 82303832]

作者

  • Z

    Zhang, Yuxin (第一作者)

    huazhong univ sci & technol

  • Z

    Zhang, Yujie

    huazhong univ sci & technol

查看全部 13 位作者收起作者
  • T

    Tao, Haisu

    huazhong univ sci & technol · southern med univ

  • Z

    Zhu, Jinghan

    huazhong univ sci & technol

  • L

    Lu, Yuanxiang

    huazhong univ sci & technol

  • C

    Cheng, Fangling

    huazhong univ sci & technol

  • X

    Xiong, Yixiao

    huazhong univ sci & technol

  • L

    Liu, Junjie

    huazhong univ sci & technol

  • C

    Cai, Guangzhen

    huazhong univ sci & technol

  • Z

    Zhang, Zhanguo (通讯)

    huazhong univ sci & technol

  • L

    Liang, Huifang (通讯)

    huazhong univ sci & technol

  • C

    Chen, Yifa (通讯)

    huazhong univ sci & technol

  • Z

    Zhang, Wanguang (通讯)

    huazhong univ sci & technol

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417